glp-1 through ro The first ever FDA-approved pill for weight loss. Now on Ro. For Important Safety Information about GLP-1 medications, including Boxed Warning, go to ro.co/safety #wegovy #glp1 Innovation on Ro. Results on

References: Enteroendocrine L Cells Sense LPS After Gut Barrier Injury to Enhance GLP-1 Secretion

Biased agonism and polymorphic variation at the GLP-1 receptor: implications for the development of personalised therapeutics

Structural modelling further suggests that additional stabilising interactions strengthen and prolong IUB447GLP-1 receptor binding compared with native GLP-1, potentially explaining its superior efficacy

The goals of GH therapy in PWS go beyond simply improving growth (119, 120)

Recommended starting dose: Discontinue other basal insulin and/or GLP-1 agonist before initiating Soliqua Patients naive to basal insulin or a GLP-1 agonist, currently on a GLP-1 agonist or less than 30 units of basal insulin daily: starting dose is 15 units once daily Patients currently on 30 to 60 units of basal insulin daily, with or without a GLP-1 agonist: starting dose is 30 units once daily Maintenance: titrate dose up or down by 2 - 4 units every week based on blood sugar goals Missed doses: resume dosing at the next scheduled dose

ImproBiome provides both soluble and fermentable fibers that work together to promote comfortable, regular elimination